We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
+25.75%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$282M
AUM Growth
-$385M
Cap. Flow
-$338M
Cap. Flow %
-120.07%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
2
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$321M
2
PHVS icon
Pharvaris
PHVS
+$16.7M
3
ELEV
Elevation Oncology
ELEV
+$707K
4
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
+$341K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$275M
$108M 38.37%
9,699,925
– –
PHVS icon
2
Pharvaris
PHVS
$2.39B
$99.1M 35.17%
4,289,304
-630,200
-13% -$16.7M
HRMY icon
3
Harmony Biosciences
HRMY
$2.04B
$34.8M 12.33%
1,035,396
– –
SLRN
4
DELISTED
ACELYRIN
SLRN
$26M 9.23%
3,852,470
– –
ELEV
5
DELISTED
Elevation Oncology
ELEV
$13.8M 4.91%
2,696,133
-218,122
-7% -$707K
RYZB
6
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-5,158,162
Closed -$321M
IMPL
7
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
– –
-2,759,791
Closed -$341K

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q1 2024 Portfolio in Review

As of Q1 2024, venBio Partners held 7 positions worth $282M, down 58% from $667M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners withdrew a net $338M in Q1 2024, closing 2 positions and reducing 2 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $321M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's biggest Q1 2024 reduction was Pharvaris, cutting an estimated $16.7M.
  • venBio Partners fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $321M.
  • venBio Partners's ten largest holdings make up 100% of its $282M portfolio in Q1 2024.
  • venBio Partners opened 0 new positions and closed 2 in Q1 2024.
  • venBio Partners's portfolio value fell 58% quarter-over-quarter to $282M.

Based on venBio Partners's 13F filing for Q1 2024, filed 15 May 2024.